Biomedical Warming and Thawing Devices Market Size & Share 2025 - 2034

Biomedical Warming and Thawing Devices Market Size

The global biomedical warming and thawing devices market was valued at USD 274.3 million in 2024. The market is expected to grow from USD 297.5 million in 2025 to USD 634.9 million in 2034, at a CAGR of 8.8%.

The market is expanding due to an increase in blood banks, stem cell research, and IVF procedures that utilize cryopreserved sample handling. Furthermore, the growing incidence of chronic diseases, advancement of regenerative medicine, and wider uses of healthcare cryopreservation will increase market growth in the following years.
 

The market is witnessing an extensive rise in the use of cryopreservation in cell therapy, gene therapy, and personalized medicine. These techniques have created a strong demand for warming and thawing devices. Blood and biobanks commonly use these devices to maintain the quality of cryopreserved samples such as blood products, stem cells, and embryos that are important for research and treatment. Moreover, the growing number of chronic diseases such as cancer and cardiovascular diseases further increases the potential market for these devices in hospitals and transfusion centers.
 

In addition, the increasing investment in stem cell research and regenerative medicine is positively influencing the growth of the biomedical warming and thawing devices market. For instance, private and government bodies are sponsoring research to build advanced thawing devices to enhance sample preservation and utilization. Furthermore, there is an increase in cases of infertility, which has increased the demand for IVF procedures. Warming and thawing devices are essential for handling oocyte, embryo, and semen samples, and they aid greatly in these processes. The level of control that needs to be maintained while handling samples in these procedures is what primarily drives the market.

The effectiveness of thawing devices that use the latest automation and remote monitoring innovations is remarkable. These thawing devices within their biomedical context refer to biomedical thawing and warming devices. Their range of thawed specimen includes blood products, stem cells, embryo(s), and tissues, all managed with remarkable precision. The thawing process is crucial in blood bank procedures, regenerative medicine, IVF, and several other research programs; however, sample integrity in terms of sterility and viability poses a significant challenge.  
 

Biomedical Warming and Thawing Devices Market Trends

• Biotechnology improvements are leading to advanced workflows in biomedical warming and thawing. Remote sample monitoring and control through automation and remote access using IoT technology allow mobile control over specimen handling. Both systems provide detailed documentation useful to many researchers and healthcare providers.
   
• Automation creates new opportunities for control and sample handling without direct supervision. These new developments have increased interest in mobile devices like tablets and smartphones, shifting focus toward compact ergonomic devices. This supports and maintains performance standards that are important in decentralized healthcare.
   
• The change from water-based to dry methods for warmers and thawers is less harmful. These dry systems are preferred, less dangerous, and more useful in sensitive places like hospitals and biobanks.
   
• Companies are actively adopting environment-friendly policies that use green materials and energy-efficient technologies in their equipment.
   
• There is growing interaction between market players and research institutions, which is speeding up market growth. Other important partnerships include those aimed at developing thawing devices for advanced cell and gene therapies. Such partnerships show the precision focus that is common in the industry.
   
• The increased use of precision medicine raises the demand for more advanced biomedical thawing and warming devices. It plays an important role in managing frozen samples like stem cells, which are vital in most custom treatments such as cell and gene therapies. There is increasing trust in personalized medicine approaches, leading to higher demand for reliable thawing and warming systems.
   
• Development of warming and thawing devices is focused on compact and portable models for military and rural sector ambulances and clinics.
   

Biomedical Warming and Thawing Devices Market Analysis

Based on product, the market is segmented as thawing devices and warming devices. The thawing devices segment generated revenue of USD 164.6 million in 2024.
 

• The market will continue to have a large share of thawing devices because they are crucial to maintain the usefulness of cryopreserved samples. Blood banks utilize these devices for the thawing plasma and platelets needed for transfusion and surgical procedures during emergencies. Automation in thawing systems with temperature control features separates the instruments into those for controlled low-temperature thawing, ensuring sensitive samples like stem cells and embryos remain at the top of the list of most important components.
   
• Additionally, the development of regenerative medicine and stem cell treatments strengthens the market share of thawing devices. These systems are needed to maintain the viability of stem cells when cryopreserved stem cells used in cell and gene therapy applications are thawed. The growing use of thawing devices in biobanks and IVF clinics also supports the leading position of such devices in the market.
   

Based on mode, the biomedical warming and thawing devices market is segmented as manual and automatic. The manual segment is expected to drive business growth and expand at a CAGR of 8.6%, reaching over USD  412.9 million by 2034.
 

• The manual segment holds large market share because it is cost effective and appropriate for small-scale operations. In developing regions with financial limitations and little access to automation, manual warming and thawing devices will remain the main option. These basic tools can be operated by small laboratories and clinics because they do not need complex infrastructure. 
   
• Moreover, other manual devices are more suitable for the samples that require constant attention during thawing or warming periods, like semen and tissue samples. Their low-maintenance policies aid emerging market economies.
   

Based on sample, the biomedical warming and thawing devices market is segmented as blood products, ovum/embryo, semen, and other sample types. The blood products segment is expected to drive business growth and expand at a CAGR of 8.7%, reaching over USD 291.8 million by 2034.
 

• The market is largely governed by the combination of blood products due to the high need for blood transfusions and blood-related procedures. Blood banks and transfusion facilities use warming and thawing apparatuses that prepare plasma, platelets, and red blood cells for clinical procedures. These technologies maintain the safety and efficacy of blood products needed during emergency and routine medical procedures.
   
• In addition, substantial growth in the number of surgical procedures and cancer treatments has augmented the need for such devices. Hospitals and biobanks need these devices because of the wide usage of blood products, which forms the basis of their growing market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the biomedical warming and thawing devices market is segmented as blood banks and transfusion centers, hospitals, research laboratories, pharmaceutical companies, and other end users. The blood banks and transfusion centers segment dominated the market with a revenue share of 31.9% in 2024.
 

• Blood banks and transfusion centers are the largest users of warming and thawing blood product devices, and they hold the highest market share. These facilities regularly handle large volumes of plasma and platelet thawing, which is necessary for emergency and surgical transfusions. Regular blood donation drives ensure that surgeons can receive blood within minutes, which has helped strengthen this segment's dominance.
   
• Additionally, new thawing systems such as automated and rapid thawing devices are helping blood banks improve their operational efficiency.
   

North America: The U.S. biomedical warming and thawing devices market accounted for USD 87 million in 2024 and is anticipated to grow at a CAGR of 8.4% between 2025 to 2034 period.
 

• The U.S. holds a significant share in the North American region due to the growing cases of chronic disorders and a high volume of surgical procedures. The hospitals and healthcare institution blood banks in the U.S. are adopting modern thawing systems to manage the higher demand for blood products in emergencies and surgical procedures.
   
• Moreover, the focus of Cytiva and Helmer Scientific on developing thawing solutions for the U.S. healthcare systems has increased emphasis on applied research and development in regenerative medicine and in-vitro fertilization supporting thawing systems needed.
   

UK biomedical warming and thawing devices market is projected to grow remarkably in the coming years.
 

• The UK market is growing due to the adoption of thawing devices in blood banks and research laboratories. The expansion of biobank capabilities in the country, particularly in sample storage and management, is increasing the demand for these devices. The UK Biobank, which preserves biological samples for scientific research, has created a need for advanced thawing methods for biological samples.
   
• The increasing cases of infertility and the use of IVF procedures in the UK have increased the demand for thawing systems used in embryo and oocyte manipulation.
   

China holds a dominant position in the Asia Pacific biomedical warming and thawing devices market.
 

• The growth of China's market is driven by increased investments in biotechnology and expanding healthcare infrastructure. The growing network of blood banks and transfusion centers in the country increases the need for plasma and platelet thawing devices.
   
• Advanced stem cell research and regenerative medicine is actively supported by the government, which helps develop advanced thawing and warming systems. Chinese businesses are working with global partners to create solutions for the domestic market.
   

Biomedical Warming and Thawing Devices Market Share

The market for thawing and thawing workstation devices in the health and medicine domain is growing with new developments and competitive changes. Currently, the three leading firms - Helmer Scientific, Cytiva, and Boekel Scientific - hold around 40% of the market due to their product portfolios, geographic coverage, and continuous efforts for advancement. These firms have positioned themselves as leaders by developing new sample management solutions that incorporate the latest technology to meet user requirements for accuracy, efficiency, and safety.
 

Helmer Scientific has been adding automation to its plasma thawing systems to improve functionality in hospitals and blood banks. Their processes need precision and reliable high-throughput workflows. With the growth of smaller laboratories, Boekel Scientific has strengthened its position by releasing cost-effective thawing systems for small and medium-sized labs that are simple yet multifunctional.
 

Industry trends are changing because of new strategic partnerships. Partners work with biotech companies and with academic research institutions to provide new solutions for diverse needs like regenerative medicine or biobanking. Working with leading research organizations, devices for thawing stem cells preserving their viability and therapeutic usefulness were developed by Cytiva.
 

The market shows regional expansions and mergers. The strategic focus of major companies is moving toward the fast-developing Asia-Pacific region, particularly China and India, which are seeing high healthcare infrastructure spending. To expand their market access, integrate new technologies, and increase growth, companies are acquiring later-stage firms and startups.
 

Sustainability initiatives are increasing. Companies are developing environmentally friendly devices and energy-efficient equipment. Innovation continues while competition remains strong. Market leaders spend significant resources to protect their positions from new players who bring innovative concepts in specialized fields. This ongoing competition between established and new companies drives the market forward.
 

USP’s of Major Market Companies

• Cytiva provides automated thawing equipment for cell and gene therapy processes. The company focuses on stem cell therapy and CAR-T cell therapy where their solutions are compatible with bioprocessing workflows and assist in the development of tailored medicine. Their products come with temperature control systems that protect and retain the incremented stem cells, sap, cells, and cell clusters.
   
• Eppendorf manufactures heating devices for use in labs and clinics. Their thawing systems come with temperature control sensors that maintain and monitor the sample's safe condition. The systems are portable, user-friendly, and designed for small to mid-sized laboratories throughout the world.
   
• Haier Biomedical provides thawing products that are more affordable, economically cost-effective, and energy-efficient compared to similar counterparts. The company designs green products and sells to healthcare centers in various regions using its global distribution network.
   
• PHCbi Designs thawing and warming devices to be used in biobanks and clinical research. Their systems utilize cooling and thawing techniques to maintain the samples. The company offers dependable sample management services for those requiring adequate sample management.
   
• The thawing devices produced by Sartorius integrate with bioprocessing workflows. The company's innovations are driven by engineering and research and development which focus on applications within the pharmaceuticals and biotechnology sectors.
   
• Thermo Fisher Scientific provides thawing devices for blood products, vaccines, and cell therapies. Their products have built-in protective features as well as rapid thawing capabilities. Thermo Fisher is known in the biomedical sample handling industry for its global operations and product development.
   

Biomedical Warming and Thawing Devices Market Companies

Prominent players operating in the biomedical warming and thawing devices industry include:

• Arctiko
• Barkey
• BioCision
• BioLife Solutions
• BOEKEL
• Cytiva
• eppendorf
• Haier Biomedical
• Helmer SCIENTIFIC
• IVF tech
• LABCOLD
• PHCbi
• SARTORIUS
• Thermo Fisher
   

Biomedical Warming And Thawing Devices Industry News:

• In October 2024, Purdue University started construction of the William D. and Sherry L. Young Institute for Advanced Manufacturing of Pharmaceuticals' racetrack facility at the Indiana Manufacturing Institute. The groundbreaking event featured presentations from university officials. The event also marked the introduction of the Lyo2040 thawing technology roadmap, which focuses on advancing pharmaceutical and biotechnology manufacturing.
   
• In June 2024, Danish medical technology company MEQU received FDA 510(k) approval for its M Warmer System, a portable blood and IV fluid warming device. The system enables the warming of blood and IV fluids at injury sites, during patient transport, and in hospital settings, helping prevent hypothermia in hemorrhaging patients. Developed through collaboration with the Danish military and the Technical University of Denmark (DTU), the device aims to reduce hypothermia and improve survival rates and recovery outcomes for severely injured patients.
   

The biomedical warming and thawing devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 — 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Thawing devices
• Warming devices

Market, By Mode

• Manual
• Automatic

Market, By Sample

• Blood products
• Ovum/embryo
• Semen
• Other sample types

Market, By End Use

• Blood banks and transfusion centers
• Hospitals
• Research laboratories
• Pharmaceutical companies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE